The Cannabis Industry Needs A Quick Change To Meet Market Demands
President Joe Biden’s proposal to reschedule cannabis to Schedule III has ignited debates. While advocates believe this new decision will acknowledge cannabis’ therapeutic potential, increase interest in research and access to treatments, critics fear tight regulations may disadvantage small businesses and marginalized groups due to pharmaceutical dominance which may inflate prices and limit access. While both concerns are valid, it’s imperative to confront one of the cannabis industry’s most pressing issues: product quality, efficacy and safety.
The cannabis industry was thrown into confusion when a paper concluded that cannabis products don’t work for pain and are heavily contaminated with heavy metals and other toxic substances, which may jeopardize the health of users. According to the researchers, there is no evidence that CBD products reduce chronic pain and taking them is a waste of money and potentially harmful to health. Out of the 16 CBD products used during the research, 15 showed no positive pain-relieving properties. Another study published in 2022 shows that 1 in 4 CBD products were …